✦ LIBER ✦

Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance

✍ Scribed by Apostolaki, S; Perraki, M; Pallis, A; Bozionelou, V; Agelaki, S; Kanellou, P; Kotsakis, A; Politaki, E; Kalbakis, K; Kalykaki, A; Vamvakas, L; Georgoulias, V; Mavroudis, D

Book ID: 118119983
Publisher: Oxford University Press
Year: 2007
Tongue: English
Weight: 157 KB
Volume: 18
Category: Article
ISSN: 0923-7534
DOI: 10.1093/annonc/mdl502

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Detection of occult HER2 mRNA-positive t

Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance

✍ Stella Apostolaki; Maria Perraki; Galatea Kallergi; Maria Kafousi; Savvas Papado 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 100 KB

Detection of occult HER2 mRNA-positive t

Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance

✍ Stella Apostolaki; Maria Perraki; Galatea Kallergi; Maria Kafousi; Savvas Papado 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 341 KB

Molecular Detection and Prognostic Value

Molecular Detection and Prognostic Value of Circulating Cytokeratin-19 Messenger RNA–Positive and HER2 Messenger RNA–Positive Cells in the Peripheral Blood of Women with Early-Stage Breast Cancer

✍ Michail Ignatiadis; Maria Perraki; Stella Apostolaki; Eleni Politaki; Nikos Xeni 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 115 KB

Subcutaneous versus intravenous administ

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

✍ Gustavo Ismael; Roberto Hegg; Susanne Muehlbauer; Dominik Heinzmann; Bert Lum; S 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 245 KB

Final results of a multicenter phase II

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

✍ Marta Pestrin, Silvia Bessi, Fabio Puglisi, Alessandro M. Minisini, Giovanna Mas 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 246 KB